ADMA Biologics, Inc. (ADMA)
Company Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S.
pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities.
The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers.
ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 617 |
| CEO | Adam S. Grossman |
Contact Details
Address: C/o Adma Biologics, Inc., 465 State Route 17 Ramsey, New Jersey 07446 United States | |
| Phone | (201) 478-5552 |
| Website | admabiologics.com |
Stock Details
| Ticker Symbol | ADMA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001368514 |
| CUSIP Number | 000899104 |
| ISIN Number | US0008991046 |
| Employer ID | 56-2590442 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Adam S. Grossman | Co-Founder, President, Chief Executive Officer and Director |
| Dr. Jerrold B. Grossman D.P.S., Ph.D. | Co-Founder and Vice Chairman |
| Brian Lenz CPA, CPA | Executive Vice President, Chief Financial Officer and GM of ADMA BioCenters |
| Kaitlin Kestenberg | Vice President of Compliance, Project Management and Clinical Operations |
| Michael Goldstein | Senior Director and General Counsel |
| Michael Least | Vice President of Sales and Commercial Operations |
| Drew Pantello | Vice President of Marketing and Corporate Development |
| Neal C. Fitzpatrick | Vice President of Sales |
| Dr. Gene A. Wetzstein BCOP, Pharm.D. | Executive Director and Head of Scientific Engagement |
| Cyndi Tolman | Senior Vice President of Plasma Services |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2023 | 8-K | Current Report |
| Dec 12, 2023 | 8-K | Current Report |
| Nov 16, 2023 | 8-K | Current Report |
| Nov 8, 2023 | 10-Q | Quarterly Report |
| Nov 8, 2023 | 8-K | Current Report |
| Oct 2, 2023 | 8-K | Current Report |
| Aug 22, 2023 | 144 | Filing |
| Aug 18, 2023 | 144/A | Filing |
| Aug 14, 2023 | 144 | Filing |
| Aug 14, 2023 | 144 | Filing |